Kyowa Hakko Kirin is tapping the specialist expertise of the private US venture Ultragenyx Pharmaceutical to speed up the development and commercialization of potentially the first specific therapy for the rare metabolic bone disorder X-linked hyperphosphatemia (XLH).
Kyowa Hakko Kirin is tapping the specialist expertise of the private US venture Ultragenyx Pharmaceutical to speed up the development and commercialization of potentially the first specific therapy for the rare metabolic bone disorder X-linked hyperphosphatemia (XLH).
The IgG1 monoclonal antibody KRN23, discovered by the Japanese firm, is currently in the latter stages of a Phase I/II...
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
